Shares of Summit Therapeutics SMMT tanked nearly 31% on Friday after it reported mixed results from the phase III HARMONi ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

Paclitaxel is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and locally ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

As with all products, we will keep its safety under close review The Medicines and Healthcare products Regulatory Agency ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...